Tracers / [18F]AQ28A

[18F]AQ28A

Also written as [18F]AQ28A; [F-18]AQ28A
Radionuclide
F-18 t½ 109.77 min
Modality
PET
Production route
Stage
preclinical
Syntheses indexed
1

What it is

Compound class
8-bromo-1-(6-[18F]fluoropyridin-3-yl)-3,4-dimethylimidazo[1,5-a]quinoxaline radioligand
Target / mechanism
Phosphodiesterase 10A (PDE10A) PMID 27896836
Clinical application
Neurodegenerative and psychiatric diseases (preclinical brain imaging) PMID 27896836
Theranostic pair

Regulatory status

FDA
EMA (centralised)
Other approvals
Brand names

Clinical use

Typical injected activity
Uptake time

Reported in the literature. Not a dosing recommendation.

Published syntheses

ModuleCassettePurificationYield %RCP %Precursor / supplierSource
33 ± 6%nitro precursor27896836
2017 J Labelled Comp Radiopharm
we developed an automated synthesis on a Tracerlab FX F-N module — [18 F]AQ28A with high radiochemical yields (33 ± 6%)

Need this precursor?We can point you to suppliers for [18F]AQ28A, or handle the enquiry for you.

Get in touch

Quality control Preliminary — inferred from compound class

Ph. Eur. monograph
USP monograph
AppearancepHRCP HPLCRCP TLCHPLC UVRadionuclidic (HPGe)Half-lifeActivityEndotoxins (LAL)SterilityFilter integrityMolar activity
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); receptor ligand with a saturable target -> molar activity (rule); organic-phase radiosynthesis assumed from isotope/compound class, no synthesis data confirming it -> GC residual solvents (preliminary); conventional nucleophilic 18F-fluorination assumed from isotope/compound class, no synthesis data confirming K222 use -> Kryptofix test (preliminary)

Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived

Setting up quality control?We can help you scope the equipment needed to release [18F]AQ28A.

Get in touch

Notes

Added from reverse module search (stage 6); 1 article(s) with F-18.